Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Mycenax Biotech's earnings before interest and taxes (EBIT) for the
three
months ended in Dec. 2025 was NT$-46.1 Mil.
Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-420.4 Mil.
EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
Mycenax Biotech's annualizedROC % for the quarter that ended in Dec. 2025 was -5.88%.
Mycenax Biotech's annualizedROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -8.37%.
EBIT is also linked to Joel Greenblatt's definition of earnings yield.
Mycenax Biotech's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -7.10%.
Mycenax Biotech (ROCO:4726) EBIT Explanation
1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
Mycenax Biotech's annualizedROC % for the quarter that ended in Dec. 2025 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mycenax Biotech EBIT Related Terms
Mycenax Biotech EBIT Historical Data
* Premium members only.
The historical data trend for Mycenax Biotech's EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Mycenax Biotech's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mycenax Biotech EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Mycenax Biotech's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Mycenax Biotech's EV-to-EBIT falls into.
EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.
EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-420.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mycenax Biotech (ROCO:4726) has a EBIT of NT$-420.4 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Mycenax Biotech.
Is Mycenax Biotech's EBIT too high?
Mycenax Biotech's current EBIT is NT$-420.4 Mil. Overall, Mycenax Biotech has a GF Score™ of 43/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mycenax Biotech's EBIT compare to VRTX and REGN?
Mycenax Biotech's EBIT of NT$-420.4 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Mycenax Biotech. Mycenax Biotech's current EBIT is NT$-420.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mycenax Biotech stock overvalued right now?
Based on GuruFocus' analysis, Mycenax Biotech (ROCO:4726) is currently considered Possible Value Trap. The stock's GF Value™ is NT$47.88, compared to a current price of NT$24.50 — trading 48.8% below its estimated fair value. The current EBIT is NT$-420.4 Mil. Mycenax Biotech's overall GF Score™ is 43/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Mycenax Biotech (ROCO:4726), the current EBIT is NT$-420.4 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mycenax Biotech (ROCO:4726) Overvalued in 2026?
Based on GuruFocus' analysis, Mycenax Biotech stock appears to be undervalued.
The current stock price of NT$24.50 is trading 48.8% below its estimated GF Value™ of NT$47.88.
GuruFocus considers Mycenax Biotech to be Possible Value Trap.
Key valuation signals for ROCO:4726:
EBIT: NT$-420.4 Mil
GF Value™: NT$47.88 vs. price of NT$24.50 (48.8% below fair value)
No single metric tells the full story. See the ROCO:4726 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mycenax Biotech Inc is a Taiwan-based biopharmaceutical company. It is engaged in the development and manufacture of biopharmaceutical products, specializing in mammalian and microbial cell-derived biologics. The company provides services for program evaluation/confirmation, cell line development, and construction, process development technology platforms, drug characterization analysis, the establishment of testing methods, and drug production in accordance with PIC/S GMP manufacturing standards. The company's main operating region is located in Taiwan.
43GF Score
Get the complete analysis for ROCO:4726
EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4726 has been successfully added to your 
